Chapter 3

Prosthetic valves in adult patients with congenital heart disease: Rationale and design of the Dutch PROSTAVA study

Netherlands Heart Journal 2012;20:419-424

Hendrik G. Freling
Ymkje J. van Slooten
Joost P. van Melle
Barbara J.M. Mulder
Arie P.J. van Dijk
Hans L. Hillege
Martijn C. Post
Gertjan T. Sieswerda
Monique R.M. Jongbloed
Tineke P. Willems
Petronella G. Pieper
Abstract

Background Data on long-term complications in adult patients with congenital heart disease (ACHD) and a prosthetic valve are scarce. Moreover, the influence of prosthetic valves on quality of life (QoL) and functional outcome in ACHD patients with prosthetic valves has not been studied.

Objectives The primary objective of the PROSTAVA study is to investigate the relation between prosthetic valve characteristics (type, size and location) and functional outcome as well as QoL in ACHD patients. The secondary objectives are to investigate the prevalence and predictors of prosthesis-related complications including prosthesis-patient mismatch.

Methods The PROSTAVA study, a multicentre cross-sectional observational study, will include approximately 550 ACHD patients with prosthetic valves. Primary outcome measures are maximum oxygen uptake during cardiopulmonary exercise testing and QoL. Secondary outcomes are the prevalence and incidence of valve-related complications including prosthesis-patient mismatch. Other evaluations are medical history, physical examination, echocardiography, MRI, rhythm monitoring and laboratory evaluation (including NT-proBNP).

Implications Identification of the relation between prosthetic valve characteristics in ACHD patients on one hand and functional outcome, QoL, the prevalence and predictors of prosthesis-related complications on the other hand may influence the choice of valve prosthesis, the indication for more extensive surgery and the indication for re-operation.
Background

Due to the improved survival of children with congenital heart disease (CHD), the number of adults with CHD has increased and adult patients with CHD now outnumber children [1]. Prosthetic valves, mechanical or biological, are part of the treatment in many patients with CHD. Mechanical prosthetic valves may negatively influence quality of life because of the necessity for anticoagulation therapy, which can hamper the active lifestyle of young adult patients with CHD and which prevents women from going through untroubled and safe pregnancies [2]. Biological prosthetic valves are an alternative, but they have their own disadvantages, the most important of which is their high deterioration rate, especially in young patients and during pregnancy, inevitably leading to re-operation [3].

Both types of valves share another complication: prosthesis-patient mismatch (PPM). PPM is present when the effective orifice area (EOA) of the inserted prosthetic valve is too small in relation to body size. In adults with acquired heart disease, PPM is associated with increased morbidity and mortality [4]. The prevalence of PPM is probably high in adult patients with CHD, both with biological and with mechanical valves, because of somatic growth of patients after implantation of a small valve during childhood. A few small series have investigated mid- and long-term complications of prosthetic valves including PPM in children [5,6]. However, the prevalence of PPM and its consequences in adult patients with CHD are unknown.

Adult patients with CHD and a prosthetic valve differ from patients with acquired valve disease in terms of age, lifestyle and underlying disease. Additionally, the prevalence of tricuspid and pulmonary prosthetic valves is higher in adult patients with CHD. These differences may lead to a different outcome in terms of functional capacity and quality of life as well as to a distinct spectrum of long-term complications associated with prosthetic valves.

However, the influence of prosthetic valves on quality of life and functional outcome in adult patients with CHD has not been studied, and data on long-term complications are scarce [7]. We intend to study these issues in an adult population with CHD and prosthetic valves. In this article we introduce the study design and describe the rationale of the ‘Functional outcome and quality of life in adult patients with congenital heart disease and prosthetic valves (PROSTAVA) study’.
Methods

Study objectives

The primary objective of this multicentre cross-sectional observational study is to investigate the relationship between characteristics of valve prostheses (type, size, location) and functional outcome as well as quality of life in adult patients with CHD (objective 1). The secondary objectives of this study are to investigate the prevalence and predictors of PPM (objective 2) and the incidence of prosthesis-related complications (objective 3) in an adult CHD population.

Study population

Inclusion and exclusion criteria for objectives 1, 2 and 3 are shown in table 1. All patients in the Dutch national CONCOR ('CONgenital CORvitia') database with valve prostheses (homografts, heterografts and mechanical valves) are eligible to participate in this study. Of the 900 identified patients, 702 were eligible for prospective investigation; by 15 February 2012, 406 of these patients with 424 valves were included in the PROSTAVA study (figure 1).

Table 1 - Inclusion and exclusion criteria PROSTAVA

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Included in the CONCOR database</td>
<td>Age &lt; 18 years</td>
</tr>
<tr>
<td></td>
<td>Prosthetic valve</td>
<td></td>
</tr>
<tr>
<td>Objectives 1, 2</td>
<td>Patients able to understand the study procedures</td>
<td>Pregnant or &lt; 3 months after pregnancy</td>
</tr>
<tr>
<td></td>
<td>Patients willing to provide informed consent</td>
<td>Inability to complete QoL questionnaire</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inability to perform cardiopulmonary aerobic capacity testing</td>
</tr>
</tbody>
</table>

CONCOR = CONgenital Corvitia; QoL = Quality of Life
Main procedures

Objective 1

Characteristics of valve prostheses (type, size and location) will be obtained from the medical records and from echocardiographic examination. For the evaluation of functional outcome and quality of life, cardiopulmonary aerobic capacity testing (CACT), New York Heart Association functional class and the SF-36 quality of life questionnaire will be used as primary outcome measures. Confounders which may influence the quality of life and functional outcome, such as ventricular function, native valve dysfunction and rhythm disorders, will be recorded using echocardiography, magnetic resonance imaging (MRI) and 24-hour Holter recording.

Figure 1 Prosthetic valves included in the prospective part of the study by February 15th 2012. AVR = aortic valve replacement; MVR = mitral valve replacement; PVR = pulmonary valve replacement; TVR = tricuspid valve replacement.

Objective 2

To investigate the prevalence and degree of PPM, echocardiography will be used to measure the EOA and calculate the indexed EOA (iEOA = EOA/Body Surface Area). Consequences of PPM including the presence and degree of ventricular hypertrophy, ventricular and atrial volumes, and pulmonary pressures will be measured with MRI and/or echocardiography. Possible predictors of PPM will be identified from the medical records, such as underlying heart disease, type of cardiac surgery, type and size of valve prosthesis and age at implantation.
Objective 3

The inventory of the patient’s past medical history and present medical status (including current medical history and physical examination) will be used to record the incidence of prosthesis-related complications. Published guidelines will be used for the registration of complications [8]. To ensure completeness of data collection a patient interview will be used to check if any data were missed by studying the medical files; however, data that can not be verified from medical files are not qualified for entry in the database. Laboratory evaluations will be performed to obtain information on heart failure and haemolysis. To detect rhythm disorders, ventricular hypertrophy and intraventricular conduction delays, electrocardiogram and 24-hour Holter monitoring will be used. Ventricular volumes, mass and function and prosthetic valve function will be assessed using echocardiography and MRI.

Cardiopulmonary aerobic capacity testing

The parameters to be recorded are: expected and achieved VO2max, respiratory quotient, anaerobic threshold, blood pressure at rest and during exercise, and heart rate at rest and during exercise.

Quality of life questionnaire

Quality of life will be assessed using the short-form 36 health survey questionnaire. This questionnaire consists of 36 items to measure health and quality of life using a multi-item scale for eight different aspects: physical functioning, role of limitations due to physical problems, role of limitations due to emotional problems, social functioning, mental health, pain, energy/vitality and general health. Furthermore, there is a single item on changes in respondents’ health over the past year.

Echocardiography

Two-dimensional echocardiography will be performed according to current guidelines to assess the function of prosthetic and native valves, to quantify chamber dimensions and left ventricular mass, and to assess chamber function. Pulmonary artery systolic pressure will be estimated and disease-specific evaluation performed. The EOA will be determined by the continuity equation using continuous and pulsed wave Doppler. For prosthetic valves, moderate PPM in the aortic and pulmonary valve position is defined
as an iEOA of 0.65-0.85 cm²/m² and severe PPM as iEOA ≤ 0.65 cm²/m². For the mitral and tricuspid position, we will consider moderate PPM to be present when the iEOA is ≤ 1.20 cm²/m² and severe PPM when the iEOA is ≤ 0.90 cm²/m² [9, 10].

Magnetic resonance imaging

Systemic and pulmonary ventricular function, volume and mass will be determined with a steady-state free precession cine sequence in the short-axis plane. Flow dynamics, including the regurgitation fraction of the aortic and pulmonary valve, will be assessed by using velocity-encoded MR imaging distal to the prosthetic valve. It is expected that approximately 25% of the patients will have a contraindication for MRI (i.e. pacemaker).

Statistical and ethical considerations

Sample size

Because this is an explorative study in a population where the prevalence of both valve characteristics (e.g. PPM) and the values for outcome measures are yet unknown, an appropriate sample calculation is not possible. However, the populations we expect to include are sufficiently large for all valve locations; therefore, meaningful outcomes can be expected.

Statistical analysis

Continuous variables will be expressed as mean and standard deviation when normally distributed or as median with interquartile ranges in case of non-normal distribution. Categorical variables will be presented as absolute numbers and percentages. Groups will be compared by using independent Student’s t-test for normally distributed continuous variables. Mann-Whitney U test will be used for comparisons of non-normally distributed continuous variables, and χ² test or Fisher’s exact test for comparison of categorical variables. Univariate and multivariate logistic regression analysis will be performed to identify independent predictors for main outcome measures. All statistical analyses will be performed using the statistical software package SPSS version 16.0 or higher (SPSS Inc., Chicago, IL). All statistical tests are two-tailed and a P-value of < 0.05 is considered statistically significant.
Ethical considerations

The PROSTAVA study has been approved by the Medical Ethics Committee of all the participating hospitals (METc2009/270; NL29965.042.09). The study will be conducted in accordance with the Helsinki Declaration. Subjects will be asked to participate and sign a written informed consent form after having received written as well as oral information about the study.

Discussion

In the proposed PROSTAVA study, we will assess the implications of prosthetic valves in adult patients with CHD. We will have the opportunity to relate prosthetic valve characteristics to functional outcome and quality of life in a unique large-scale patient cohort. In addition we will investigate the incidence of complications related to prosthetic valve type, size and location in this adult population with CHD.

Valve type: biological or mechanical valve prosthesis

In children and young adults, biological valves are often implanted to avoid the disadvantages of oral anticoagulation therapy. The rate of structural valve degeneration is, however, high at young age. Structural valve deterioration results in progressive prosthesis dysfunction which will impair functional capacity and which ultimately leads to valve replacement. The influence of the amount and prospect of re-operations on quality of life in patients with CHD has only been studied in a relatively small population and seems to be limited [11]. However, parameters reflecting functional status are associated with satisfaction with life and perceived health [12]. Therefore we expect that structural valve deterioration in adult patients with CHD will influence quality of life through its impact on functional outcome, which we will elucidate in the PROSTAVA study.

Structural valve deterioration and re-operations can be avoided by use of mechanical prostheses. The risk of thromboembolic complications warrants the need for anticoagulation therapy resulting in an increased risk of bleeding complications. The cumulative risk of bleeding complications during life may well be high in young adults with CHD because of their long life expectancy after valve replacement. The risk of bleeding complications may be increased by the active lifestyle of many young
adult patients with CHD. Frequent international normalised ratio (INR) controls are needed with anticoagulant therapy and patients are prevented from participating in risky sports activities. Poor compliance with warfarin therapy, which is not uncommon in adolescents, can increase the risk of thromboembolic complications. Pregnancy in women with mechanical valves bears the risk of foetal loss and embryopathy when oral anticoagulants are continued throughout pregnancy, while substitution with heparin increases the risk of thromboembolic complications [13,14]. Therefore, the impact of anticoagulation therapy is probably high in this young population. Our study will provide insight into the incidence and predictors of biological and mechanical prosthesis-related complications in adult patients with CHD as well as the consequences for quality of life and functional outcome.

**Valve size: the impact of PPM**

When valve replacement is necessary in childhood, implantation of an adult-sized prosthetic valve is often not possible. With somatic growth in children, the iEOA decreases steadily until they reach adulthood. Therefore we expect that in our study population the prevalence of PPM will be high.

A few small series have investigated PPM in children [15]. However, in adult patients with CHD the prevalence and consequences of PPM are unknown. In patients with acquired valve disease, aortic PPM is associated with less improvement in symptoms and exercise capacity, less regression of left ventricular hypertrophy, more cardiac events and higher mortality [4,9,16]. Mitral PPM is associated with recurrence of congestive heart failure, pulmonary hypertension and decreased survival [10]. We expect that PPM in adult patients with CHD will further diminish the already compromised ventricular function and exercise capacity. This reduction in exercise capacity may negatively influence quality of life by limiting these patients in their daily activities. Our study will provide a comprehensive database with a long follow-up to present us with useful information on the incidence, predictors and consequences of PPM in adult CHD patients.

**Valve location: right-sided versus left-sided prostheses**

Prevalence of tricuspid and pulmonary prosthetic valves is relatively high in adult patients with CHD compared with patients with acquired valve disease. In right-sided
mechanical prostheses thromboembolic risk is presumed to be higher compared with left-sided mechanical prostheses due to lower pressures and flow velocities in the right heart. Therefore, biological valves are the preferred valve type in the tricuspid and pulmonary position in most centres. Several recent studies have reported satisfactory results in pulmonary mechanical prostheses with aggressive anti-coagulation, INR 3.0-4.5 [17,18]. However, data concerning long-term survival, and thromboembolic and bleeding complications are still limited. Available studies are small and the only large study with more than 30 patients has a short median follow-up of only 2 years. The proposed study gives the possibility to compare complications of pulmonary mechanical valves in a relatively large cohort (54 patients) and a cohort of patients with biological valves, with a long median follow-up duration of more than 6 years.

Limitations

A limitation of our study is the presence of multiple confounding factors such as the heterogeneity of patients with CHD, multiple types and locations of prosthetic valves and differences in ventricular function. Regression analysis will partially overcome this limitation. As patients who are not able to complete the CACT and quality of life questionnaire will be excluded from the prospective study, the study population will not be entirely representative for adult patients with CHD and a prosthetic valve. Another limitation comes with the use of the CONCOR database. This database started including patients with CHD in 2001. Patients who died before this date are not included, which will limit the possibility to investigate long-term mortality.

Conclusion

The PROSTAVA study is the first study to investigate the influence of prosthetic valve characteristics on functional outcome and quality of life in adult congenital heart disease patients. Our results may influence the choice of valve prosthesis, the indication for more extensive surgery and the indication for re-operation in patients with prosthesis patient mismatch.
Addendum

Magnetic Resonance Imaging

MRI is performed at least 6 months after valve implantation. Systemic and pulmonary ventricular function, volume and mass are determined with a steady-state free precession cine sequence in the short-axis plane for the left ventricle. Flow dynamics, including regurgitation fraction of the aortic and pulmonary valve, are assessed by using velocity-encoded MR imaging distal to the prosthetic valve. No contrast agent is given. Function and flow are quantitatively analyzed by the department of Radiology of the University Medical Center of Groningen using a commercial software package (QMass version, Medis, Leiden, The Netherlands). The end-systolic and end-diastolic frames were selected by visual assessment independently for the left and right ventricle. The basal slice was selected with aid of long-axis cine view images. The basal slice of the left ventricle was defined as the most basal slice surrounded for at least 50% by the left ventricular myocardium. When the pulmonary valve was visible in the right ventricular basal slice, only the portion of the right ventricular outflow tract below the level of the pulmonary valve was included. The inflow part of the right ventricle was included in the right ventricular volume. The right ventricular inflow part was distinguished from the right atrium by recognizing the trabeculated and thick right ventricular wall compared to the thin right atrial wall. Contours were drawn manually by tracing the endocardial and epicardial borders in every slice in end-systole and end-diastole. Contour tracing was aided by reviewing the multiple phase scans in the movie mode.

Discussion

We expect PPM to be uncommon in pulmonary prosthetic valves as most of these patients received relatively large prosthetic valves in their dilated right ventricular outflow tracts. However, almost all pulmonary and tricuspid valve replacements are performed using biological prosthetic valves. The main complication of this valve type is structural valve deterioration resulting in a combination of stenosis and regurgitation. Mechanical pulmonary valve prostheses show no substantial increase in gradient and regurgitation with time. Three years after pulmonary valve replacement, mechanical valve prostheses have a superior hemodynamic performance compared to homografts. With our study we can investigate whether patients with mechanical valve prosthesis also benefit in terms of right and left ventricular volumes and function, exercise
capacity and quality of life. Furthermore, recent studies reported in patients without a pulmonary valve replacement that combined right ventricular outflow tract obstruction and pulmonary regurgitation results in smaller right ventricular volumes and better ejection fraction compared to patients with isolated pulmonary regurgitation. We can investigate whether similar findings are present in patients with biological pulmonary valve replacements and structural valve deterioration.
References


